Startup Raises $4.8M to Speed Up AI Drug Discovery

Scientists have a growing problem that's actually good news: AI is discovering potential new medicines faster than researchers can test them all.

Enter 10x Science, a startup founded by three scientists who got frustrated waiting for answers in their Stanford cancer lab. They just raised $4.8 million to help drug developers figure out which AI-discovered treatments actually work.

Here's the challenge: AI tools like Google DeepMind can now predict thousands of protein structures that might become lifesaving drugs. But each candidate needs detailed testing through a complex process called mass spectrometry. The data it produces is so complicated that only highly trained specialists can interpret it, creating a massive backlog.

"You can add as many candidates as you want to the top of the funnel, but they all have to pass through this characterization process," founder David Roberts explained. "Everything needs to be measured."

The three founders worked together in a Nobel Prize winner's lab, studying how cancer cells interact with the immune system. They watched promising research slow to a crawl because analyzing molecular data took so long. So they built an AI platform that does in minutes what used to take experts hours or days.

Matthew Crawford, a scientist at Rilas Technologies, started using the tool several weeks ago. He was shocked when it figured out what protein he was testing just from his filename, then automatically found the right data online to complete the analysis. "This software is going to help keep that can of worms closed and just get them the answer they actually need," he said.

The Ripple Effect

The platform is already working with major pharmaceutical companies and academic researchers. But the real impact goes beyond saving time. By making sophisticated protein analysis accessible to smaller labs and startups, 10x Science could democratize drug development itself.

Right now, buying mass spectrometry equipment and hiring experts costs several million dollars, putting cutting-edge research out of reach for many scientists. This tool lets them access the same insights for a monthly subscription fee.

For investors, it's also a smarter bet than backing individual drugs. Most experimental treatments fail to win regulatory approval. But 10x Science gets paid whether the drugs succeed or not, because pharmaceutical companies need the characterization process regardless.

The company plans to use their seed funding to hire more engineers and refine the AI model. If they succeed, they'll help unlock thousands of AI-discovered treatments that might otherwise sit untested in digital databases.

More AI-discovered drugs tested means more shots on goal for cures we desperately need.